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Abstract
Background: Multiple myeloma (MM) is a plasma cell tumour with an approximate annual incidence of 4500 in the
UK. Therapeutic options for patients with MM have changed in the last decade with the arrival of proteasome inhibitors
and immunomodulatory drugs. Despite these options, almost all patients will relapse post first-line autologous stem cell
transplantation (ASCT). First relapse management (second-line treatment) has evolved in recent years with an expanding
portfolio of novel agents, driving response rates influencing the durability of response. A second ASCT, as part of relapsed
disease management (salvage ASCT), has been shown to prolong the progression-free survival and overall
survival following a proteasome inhibitor-containing re-induction regimen, in the Cancer Research UK-funded
National Cancer Research Institute Myeloma X (Intensive) study. It is now recommended that salvage ASCT be
considered for suitable patients by the International Myeloma Working Group and the National Institute for
Health and Care Excellence NG35 guidance.
Methods/design: ACCoRd (Myeloma XII) is a UK-nationwide, individually randomised, multi-centre, multiple
randomisation, open-label phase III trial with an initial single intervention registration phase aimed at relapsing
MM patients who have received ASCT in first-line treatment. We will register 406 participants into the trial to
allow 284 and 248 participants to be randomised at the first and second randomisations, respectively.
All participants will receive re-induction therapy until maximal response (four to six cycles of ixazomib, thalidomide and
dexamethasone). Participants who achieve at least stable disease will be randomised (1:1) to receive either ASCTCon, using
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high-dose melphalan, or ASCTAug, using high-dose melphalan with ixazomib. All participants achieving or maintaining a
minimal response or better, following salvage ASCT, will undergo a second randomisation (1:1) to consolidation and
maintenance or observation. Participants randomised to consolidation and maintenance will receive consolidation with
two cycles of ixazomib, thalidomide and dexamethasone, and maintenance with ixazomib until disease progression.
Discussion: The question of how best to maximise the durability of response to salvage ASCT warrants clinical
investigation. Given the expanding scope of oral therapeutic agents, patient engagement with long-term maintenance
strategies is a real opportunity. This study will provide evidence to better define post-relapse treatment in MM.
Trial registration: ISRCTN, ISRCTN10038996. Registered on 15 December 2016.
Keywords: Multiple myeloma, ASCT, Augmented ASCT, Randomised, Haematology, Depth of response
Background
Multiple myeloma
Multiple myeloma (MM) is a plasma cell tumour and has
an annual incidence in the UK of approximately 4500 new
cases [1]. Therapeutic options for patients with MM have
changed in the last decade with the arrival of potent novel
agents such as proteasome inhibitors and immunomodula-
tory drugs (IMiDs) [2]. Despite the depth of responses
(DoRs) obtained with these strategies, almost all patients
will relapse post first-line autologous stem cell transplant-
ation (ASCT). The most appropriate strategy as first relapse
management (second-line treatment) has evolved in recent
years with an expanding portfolio of novel agents, driving
response rates influencing the durability of response (DuR).
A second ASCT, as part of relapsed disease management
(salvage ASCT), has been shown to prolong the
progression-free survival (PFS) and overall survival (OS) fol-
lowing a proteasome inhibitor-containing re-induction regi-
men, in the Cancer Research UK-funded National Cancer
Research Institute (NCRI) Myeloma X (Intensive) study [3].
Updated analysis showed significant improvement in second
PFS amongst a salvage ASCT group of 67 months [52, ∞)
vs. 35 months [31–43] in the weekly cyclophosphamide
group. This result was backed up with a reduced hazard ra-
tio (HR) of 0.37 and a statistically significant median differ-
ence of 15 months (67 months, 95% confidence interval, CI
[55, ∞) vs. 52 months, 95% CI [42, 60]) in overall survival,
in favour of salvage ASCT therapy with a reduced HR of
0.56 (0.35–0.90) [4]. The salvage ASCT activity in the UK
has risen as a consequence of this trial and its findings, as
evidenced by the British Society of Blood and Marrow
Transplantation (BSBMT) data registry analysis [5]. It is
now recommended that salvage ASCT be considered for
suitable patients by the International Myeloma Working
Group (IMWG) [6] and the National Institute for Health
and Care Excellence (NICE) NG35 guidance [7].
Tackling the unmet needs of existing studies
Two clear areas of unmet need arose from the Myeloma
X study. Firstly, although superior to non-ASCT consoli-
dation, both the DoR and DuR post-salvage ASCT were
inferior to those reported in first-line treatment. This
has been reported in phase III collaborative studies and
national/international transplant registries. Hence, the
question remains of how to utilise novel agents to aug-
ment this effect, aiming to achieve similar DoR and DuR
to those seen in first-line treatment. Furthermore, in the
Myeloma X study, for patients with evidence of molecu-
lar high-risk disease (IGH, TP53 and MYC rearrange-
ments), the DuR post-salvage ASCT was compromised,
despite obtaining similar DoR to those for patients with
standard-risk disease [5].
Therapy for relapsed MM using ASCT
Currently, there are three trials registered on the
ClinicalTrials.gov website involving ASCT in the salvage
setting. One study (NCT01745588) aims to compare sal-
vage ASCT with the IMiD pomalidomide as a maintenance
schedule against a non-ASCT strategy of pomalidomide,
clarithromycin and dexamethasone. The second trial
(NCT01242267) aims to address the augmentation of high-
dose melphalan with increasing doses of thalidomide in a
phase I/II setting. The third trial (NCT00938626) aims to
utilise a bi-specific antibody to CD3 and CD20 to augment
T cell activation post-salvage ASCT re-infusion in a phase
I/II setting, again not addressing the key issues raised
above. These trials will report in the early years of recruit-
ment of this study, and their results will be monitored
closely. Each of these studies is USA-based and, hence, may
have limited impact on UK practice.
Consolidation and maintenance therapy
Novel agents including proteasome inhibitors and IMiDs
are now routinely utilised as part of the induction regi-
men prior to ASCT, and this has resulted in substantial
improvements in the DoR achieved before transplant in
first-line treatment. The only data representing their im-
pact in second-line ASCT is that published by the Mye-
loma X study group [5]. Given that DoR is prognostic
for OS, a number of studies have been conducted (or are
ongoing) to investigate the use of novel agents as
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consolidation and maintenance therapy after first-line
ASCT [8]. To date, most clinical trials have reported an
increase in PFS (and even OS) in relation to post-ASCT
consolidation/maintenance. The reported PFS from
Myeloma X is shorter than that generally reported in
first-line treatment, though Myeloma X did not use
post-ASCT consolidation or maintenance.
The question of how best to maximise the DuR to salvage
ASCT warrants clinical investigation. Given the expanding
scope of therapeutic agents with differing modes of delivery
(intravenous (IV) vs. subcutaneous (SC) vs. oral) combined
with the potential for community-based therapy delivery,
patient engagement with long-term maintenance strategies
becomes a real opportunity. However, an evidence basis for
the efficacy and thus the incorporation of further post-
ASCT therapy is needed. The second question is to estab-
lish which patients benefit and, more importantly, which
patients do not benefit from salvage ASCT. There is some
evidence that molecular risk stratification at relapse after a
prior transplant may delineate subgroups where a second
transplant offers no advantage in terms of DuR. This clearly
requires a more in-depth examination [9], as, currently,
there is no evidence basis to make a clinical judgment
about the use of consolidation or maintenance in the sal-
vage ASCT setting.
Ixazomib (MLN9708)
Ixazomib (NINLARO®, Takeda Pharmaceutical Company)
is a next generation, small molecule inhibitor of the 20S
proteasome that is under development for the treatment of
MM and other haematologic and non-haematologic dis-
eases. Inhibition of the 20S proteasome has been validated
as a therapeutic target for the treatment of malignancies
using VELCADE® (bortezomib) for injection [10]. In an ef-
fort to broaden activity against a wider range of tumour
types and increase activity in tumour types where VEL-
CADE has shown activity, Takeda has developed the prote-
asome inhibitor MLN9708 (ixazomib), formulated for both
IV and oral administration. Ixazomib is structurally different
from VELCADE and refers to the biologically active, bo-
ronic acid form of the drug. The emerging safety profile in-
dicates that ixazomib is generally well tolerated. The
adverse events (AEs) are consistent with the class-based ef-
fects of proteasome inhibition and are similar to what has
been previously reported withVELCADE, though the sever-
ity of some, for example peripheral neuropathy, is less.
While some of these potential toxicities may be severe, they
can be managed by clinical monitoring and standard med-
ical intervention or, as needed, dose modification or
discontinuation.
It is therefore scientifically appropriate to utilise a prote-
asome inhibitor and IMiD combination as re-induction
therapy to set the platform to assess the impact of
conditioning augmentation and post-transplant consolida-
tion/maintenance strategies. In designing the trial, we
sought to evaluate the impact of a novel proteasome inhibi-
tor that will facilitate both the clinical benefit and the pa-
tient experience with regards to deliverability of the
treatment schema. Ixazomib, an orally active boronate-
based reversible inhibitor of the proteasome, has shown sin-
gle agent activity in phase I/II studies alongside combin-
ation therapy with dexamethasone and more recently
IMiDs [11–13]. More recently, the combination of ixazomib
and the IMiD lenalidomide was reported by Kumar and col-
leagues in combination with dexamethasone in the first-line
setting [14]. The TOURMALINE-MM1 study on the use of
oral ixazomib, lenalidomide and dexamethasone for re-
lapsed MM showed that at approximately 15 months
follow-up the ixazomib regimen group had a statistically
significant PFS advantage over the group taking the
placebo-containing comparison (21.4 months vs. 9.7
months, respectively), with an HR of 0.54 and a 95% CI
[0.32, 0.92] favouring ixazomib, with OS data not yet ma-
ture for analysis [15]. Thalidomide, the first-in-class IMiD,
is more affordable and a justifiable choice given that the
only other phase III randomised controlled trial (RCT) in
the setting of first relapse post-ASCT demonstrated that
bortezomib gave added benefit to the combination of
thalidomide and dexamethasone [6]. In addition, a
significant proportion of patients entering this proposed
trial could have received lenalidomide maintenance in the
first-line Cancer Research UK-funded NCRI study
(Myeloma XI). Ixazomib in combination with thalidomide
and dexamethasone is currently being studied in the
HOVON 126MM study (http://www.hovon.nl/studies/
studies-per-ziektebeeld/mm.html?action=showstudie&s-
tudie_id=103&categorie_id=3), which is currently open
to recruitment amongst patients not suitable for high-
dose therapy. The use of ixazomib in the maintenance
setting was reported by Kumar and colleagues at the
American Society of Haematology meeting in December
2014, demonstrating efficacy and tolerability in previously
untreated patients (http://www.bloodjournal.org/content/
124/21/82). The HOVON 126MM study also includes a
maintenance phase randomisation comparing ixazomib
and a placebo.
Methods/design
Trial aims and objectives
The Myeloma XII (ACCoRd) study aims, firstly, to seek
improvement in DoR through augmenting the condi-
tioning regimen and, secondly, to induce more durable
responses in the salvage setting via a consolidation/
maintenance strategy. Pre-clinical models [16, 17] and
first-line early phase studies have demonstrated that a
proteasome inhibitor can augment the tumouricidal ef-
fects of melphalan by inhibiting the DNA-damage repair
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mechanism employed by malignant plasma cells to
minimise the impact of melphalan [18, 19]. Such aug-
mentation of high-dose melphalan with a proteasome
inhibitor is key to delivering the impact on DoR. The
augmented ASCT dosing schedule to be used within this
trial is considered a pragmatic choice which somewhat
reflects other augmented ASCT regimens utilising
VELCADE, with the exception that ixazomib will not be
given post-graft due to bioavailability concerns such as
absorption. The major aim is to attempt to extend DuR
towards that seen after first-line ASCT (approximately
30 months PFS) [20]. Such strategies would use ixazo-
mib, which is orally active and thus patient-friendly. A
positive result from this trial would not only change
clinical practice, but would be a deliverable treatment
schema which is more patient-friendly in terms of lim-
ited hospital attendances.
This study will determine whether augmenting the
conditioning and adopting a consolidation/maintenance
strategy can have a significant impact on the DoR and
DuR in all patients deemed suitable for salvage ASCT.
The impact on patients with molecular high-risk
markers will also be evaluated.
The primary objectives of this study are to determine
the impact on DoR: < very good partial response (VGPR)
vs. ≥VGPR when salvage ASCT conditioning is aug-
mented by the addition of a proteasome inhibitor, as
well as the influence of a consolidation and maintenance
strategy on the DuR: PFS. The secondary objectives of
this study are to assess OS, time to disease progression
(or on trial PFS), overall response rate to ixazomib, thal-
idomide, dexamethasone (ITD) re-induction, time to
next treatment (TTNT), second progression-free sur-
vival (PFS2), DuR, minimal residual disease (MRD)
negative rate post re-induction, post-ASCT and conver-
sion after ITD consolidation, as well as to look at en-
graftment kinetics, toxicity and safety of the treatment
regimens and quality of life (QoL).
Ixazomib dose rationale
The lack of a discernible relationship between body sur-
face area (BSA) and ixazomib clearance over a relatively
wide BSA range (1.4–2.6 m2) indicates that total sys-
temic exposure (area under the curve, AUC), following
fixed dosing, should be independent of the individual pa-
tient’s BSA. Therefore, BSA is not expected to affect
maximum plasma drug concentration (Cmax) or AUC
after IV administration or oral dosing, and thus fixed
dosing is appropriate for both oral and IV routes of ad-
ministration. The clinical development of ixazomib has
therefore transitioned from the use of BSA-based dosing
to fixed dosing in all recently initiated Takeda phase I/II
studies (e.g. Studies C16005 phase II, C16007, C16008
and C16009). Accordingly, the starting dose of ixazomib
in the ACCoRd study is a fixed dose of 4.0 mg, on the
basis of the recommended dose of 2.23 mg/m2 (using a
mean patient BSA of 1.86 m2 from the 2208 patients
with MM in VELCADE clinical studies for conversion to
a fixed dose).
Translational research (host and biomarker exploration)
ACCoRd protocol incorporates four planned transla-
tional research studies:
 Biomarker exploration of prognosis determination:
interphase fluorescent in situ hybridisation (iFISH)
vs. next generation sequencing (NGS)-based
molecular analysis
 MRD detection: comparative analysis of multi-
parameter flow cytometry (MFC) and NGS-based
molecular analysis
 Biomarker discovery for proteasome inhibitor
sensitivity
 Immune biomarker discovery: exploration of
immune functional assessment, including immune
senescence, in relation to patient outcomes and
response to therapy.
Trial design
The ACCoRd study is a UK-based, individually rando-
mised, multi-centre, multi-stage, open-label phase III
trial with an initial single intervention registration phase
aimed at patients with relapsed MM who wish to
undergo second-line treatment. A total of 406 partici-
pants will be registered into the trial to allow 284 partic-
ipants to be randomised at the first randomisation (R1)
and 248 participants to be randomised at the second
randomisation (R2).
All participants will be registered at trial entry and
will receive re-induction therapy with four to six
28-day cycles of ITD in order to reach maximum re-
sponse. Participants who achieve at least stable disease
(SD), as described by IMWG criteria, will be rando-
mised on a 1:1 basis to receive either ASCTCon, using
melphalan, or ASCTAug, using melphalan along with
ixazomib. All participants achieving or maintaining a
minimal response (MR) or better, following trial ASCT,
will undergo a second randomisation to consolidation
and maintenance or no further treatment on a 1:1 basis.
Participants randomised to consolidation and mainten-
ance will receive consolidation with two 28-day cycles
of ITD and maintenance with ixazomib until disease
progression. Figure 1 presents a flowchart of the
ACCoRd study and Figure 2 provides the schedule of
enrolment, interventions and assessments for the study.
Additional file 1 presents the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
checklist.
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Trial population
The ACCoRd study aims to investigate the aforementioned
treatment strategy within a population of participants with
measurable, by IMWG criteria, relapsed MM requiring
therapy who had undergone ASCT in first-line treatment
and progressed for the first time at least 12 months after
undergoing ASCT. The study will be conducted within an
adult population (18 years or older), capable of giving writ-
ten informed consent, with Eastern Cooperative Oncology
(ECOG) Performance Status (ECOG PS) 0–2 and adequate
full blood count (FBC), as well as satisfactory renal, hepato-
biliary, pulmonary and cardiac function.
To be eligible for registration into the re-induction phase
of the trial, participants must meet all of the inclusion cri-
teria and none of the exclusion criteria outlined in Table 1.
At the end of re-induction therapy, patients will be
assessed for response. Patients achieving at least SD and
fulfilling the eligibility criteria (Table 2) for continuation
on trial will proceed to first randomisation (R1).
At approximately 100 days post-ASCT, patients will be
assessed for response. A minimum of 248 patients
achieving or maintaining at least MR and fulfilling eligi-
bility criteria (Table 3) for continuation on trial will
proceed to second randomisation (R2).
Sample size
There will be 406 participants registered in the trial to en-
sure that 284 participants can pass through the first ran-
domisation. This allows for 5% of participants having
progressive disease (PD) after re-induction (1.4% had PD
after bortezomib, doxorubicin and dexamethasone (PAD)
re-induction in Myeloma X), 20% of participants mobilising
insufficient cells for ASCT and 5% dropout overall through-
out the trial.
In Myeloma X, 60% achieved VGPR response or
better after ASCT. A total of 91 participants are re-
quired in each arm to detect an increase of 20%
(from 60 to 80%) in ≥VGPR rate in the ASCTAug
Fig. 1 ACCoRd study flowchart
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arm with 80% power at the two-sided 5% significance
level [21] for first randomisation (R1).
The described minimum clinically relevant difference is
reasonable given what has been observed in other trials;
e.g. an upgrade in complete responses (CRs) of 26% was
observed by Roussel and colleagues where high-dose mel-
phalan was augmented by IV bortezomib in a phase II
study in the front-line setting (comparing the impact with
that of matched historical controls receiving high-dose
melphalan alone) [19]. Therefore, the estimation of a 20%
increase in ≥VGPR rate seems reasonable to hypothesise.
The second randomisation requires the greatest number
of participants and hence determines the number of par-
ticipants required to enter the first randomisation and the
number of registered participants entering the trial. A
total of 284 participants should be allocated at R1 to en-
sure 248 participants are available at the second random-
isation (R2). Randomising 284 participants at R1 means
that we have greater than 95% power to identify the clinic-
ally relevant difference of 20% (from 60 to 80%) in ≥
VGPR rate, or 172 participants being randomised to R1 in
order to randomise at least 150 participants in R2 to
power the trial at 80% to detect a smaller increase in rate
of 16% (from 60 to 76%). This calculation accounts for
12.5% of participants suffering PD after ASCT or failing to
achieve at least MR after re-induction and ASCT (7.8%
had a response of ≤ SD after ASCT in Myeloma X).
A median PFS of 24 months was observed in the
ASCT arm in Myeloma X amongst those participants
achieving ≥VGPR. R2 in ACCoRd is 3 months later than
Fig. 2 Schedule of enrolment, interventions and assessments
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randomisation in Myeloma X; hence, the study is
powered to detect a difference in median PFS of 9
months from R2 where that would be expected to be 21
months after R2 in those participants receiving no
further consolidation and maintenance treatment and 30
months after R2 in those participants receiving further
consolidation and maintenance. Therefore, 192 events
are required for 80% power [22]. As a result, 248
participants (124 per arm) are required to detect a 33%
reduction in hazard with 80% power at the two-sided 5%
significance level (HR = 0.67) at minimum 2 years
follow-up.
The increase in median PFS of 9 months is within the
range (7–10 months) of improvements observed with
maintenance therapy in first-line myeloma treatment
[23, 24]. In addition, note that the proposed protocol
treatment includes both further consolidation and main-
tenance, and hence the anticipated difference could rea-
sonably be expected to be within this range even in
participants with relapsed disease.
Increased follow-up also allows evaluation of protocol
treatment and OS as a key secondary endpoint. The 248
participants randomised at R2 provide almost 80%
power at a significance level of 0.05 to detect a 15%
Table 1 ACCoRd study registration inclusion and exclusion criteria
Inclusion criteria
1. Diagnosed with relapsed MM (with measurable disease
according to IMWG criteria) previously treated with ASCT)
2. First progressive disease (PD) at least 12 months following first
ASCT, requiring therapy
3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0–2
4. Aged at least 18 years
5. Participants must have the following blood results within 14 days
before registration:
(a) Absolute neutrophil count (ANC) ≥ 1 × 109/L
(b) Platelet count ≥ 75 × 109/L. If the participant has ≥ 50% bone
marrow infiltration, a platelet count of ≥ 50 × 109/L is allowed.
Platelet transfusions are not allowed within 3 days before registration
in order to meet these values
6. Adequate renal function within 14 days before registration:
(a) Creatinine clearance ≥ 30 ml/min (calculated according to the
Cockcroft-Gault equation or other locally approved formula)
7. Adequate hepatobiliary function within 14 days before registration:
(a) Total bilirubin < 2 × upper limit of normal (ULN)
(b) Alanine aminotransferase (ALT) < 2 × ULN
8. Adequate pulmonary function within 14 days before registration:
(a) Adequate respiratory functional reserve (delineated by carbon
monoxide transfer coefficient (KCO)/diffusing capacity for carbon
monoxide (DLCO) (carbon monoxide diffusion in the lung)
of ≥ 50%). No evidence of a history of pulmonary disease. If a
significant history, then a review by a respiratory medicine
physician is required
9. Adequate cardiac function within 12 weeks before registration:
(a) Left ventricular ejection fraction (LVEF) ≥ 40%. Note: repeat
confirmation of cardiac function is needed if treatment is given
between this assessment and registration
10. Female participants who:
(a) Are not of childbearing potential, OR
(b) If they are of childbearing potential, agree to practice two effective
methods of contraception, at the same time, from the time of
signing the informed consent form until 90 days after the last dose
of study drug, OR
(c) Agree to practice true abstinence when this is in line with the
preferred and usual lifestyle of the subject. (Periodic abstinence
[e.g. calendar, ovulation, symptothermal, post-ovulation methods]
and withdrawal are not acceptable methods of contraception.)
Male participants, even if surgically sterilised (i.e. status post-vasectomy),
must agree to one of the following:
(a) Agree to practice effective barrier contraception during the entire
study treatment period and through 90 days after the last dose of
study drug, OR
(b) Agree to practice true abstinence when this is in line with the
preferred and usual lifestyle of the subject. (Periodic abstinence
[e.g. calendar, ovulation, symptothermal, post-ovulation methods]
and withdrawal are not acceptable methods of contraception.)
Contraception for female and male participants must be in accordance
with (and with consent to) the Celgene Thalidomide Pregnancy
Prevention Programme
11. If female and of childbearing potential, must have a negative
pregnancy test performed by a healthcare professional in
accordance with the Celgene Thalidomide Pregnancy Prevention
Programme
12. Patients agree not to receive other clinical trials treatment, including
investigational medicinal products (IMPs) not included in this trial,
within 30 days of trial registration and throughout the duration of
the trial, until disease progression
13. Able to provide written informed consent
Exclusion criteria
1. Received prior second-line therapy for their relapsed disease other
than local radiotherapy, therapeutic plasma exchange or
dexamethasone (up to a maximum of 200 mg is allowed but not
within 30 days prior to registration). Radiotherapy sufficient to
Table 1 ACCoRd study registration inclusion and exclusion criteria
(Continued)
alleviate or control pain of local invasion is permitted, but must not
be within 14 days before registration. Patients who have received
hemi-body radiation or similar since relapse will not be eligible
2. ≥ Grade 2 peripheral neuropathy within 14 days before registration
3. Known HIV seropositivity
4. Known resistance, intolerance or sensitivity to any component of the
planned therapies
5. Any medical or psychiatric condition which, in the opinion of the
investigator, contraindicates the participant’s participation in this
study
6. Previous or concurrent malignancies at other sites (excluding
completely resected non-melanoma skin cancer or carcinoma in situ
of any type, such as cervical cancer)
7. Pregnant, lactating or breast-feeding female participants
8. Failure to have fully recovered (i.e. ≤ Grade 1 toxicity) from the
reversible effects of prior chemotherapy
9. Major surgery within 14 days before registration
10. Central nervous system involvement with myeloma
11. Ongoing or active infection requiring systemic antibiotic therapy or
other serious infection within 14 days before registration
12. Evidence of current uncontrolled cardiovascular conditions, including
uncontrolled hypertension, uncontrolled cardiac arrhythmias,
symptomatic congestive heart failure, unstable angina or myocardial
infarction within the past 6 months
13. Systemic treatment, within 14 days before the first dose of ixazomib,
with strong CYP3A inducers (e.g. rifampin, rifapentine, rifabutin,
carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or
St. John’s wort
14. Known gastrointestinal (GI) disease or GI procedure that could
interfere with the oral absorption or tolerance of ixazomib, including
difficulty swallowing
15. Patients who have previously been treated with ixazomib or
participated in a study with ixazomib whether treated with ixazomib
or not
16. Participant has current or prior hepatitis B or C infection
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increase in OS at 5 years after R2 (from an estimated
59% in Myeloma X up to 74% in ACCoRd). A total of 96
events are required for 79% power at minimum 4 years
follow-up for all participants.
The 284 participants who undergo R1 will receive ran-
domised ASCT (conventional or augmented) treatment.
At 100 days post-ASCT, these participants will be
assessed for response to treatment. In order to proceed
to the next stage of the trial, R2, participants must have
achieved a minimum of MR (according to the IMWG
criteria). Based on experience of Myeloma X, we antici-
pate that not all participants will maintain at least SD. In
order for the study to retain enough power for the statis-
tical analysis, we require a minimum of 248/284 partici-
pants to meet the criteria to proceed to R2. This
constitutes an approximate dropout rate of 10%.
Recruitment and consent
Participants will be recruited from 70 research centres
from around the UK, which were identified via a feasibil-
ity assessment to determine the most appropriate cen-
tres to participate in the trial.
Potential participants will be identified by the clinical
team at participating centres based on their diagnosis of
relapsed MM and subsequently approached during
standard clinic visits for management of their disease, as
well as being provided with verbal and written details
about the trial. Assenting patients will then be invited to
provide informed, written consent. Consenting partici-
pants will be formally assessed for eligibility, and eligible
participants can be registered.
Eligibility will be confirmed prior to registration and
each randomisation, with the information being re-
corded in the participant’s medical records and on the
relevant Case Report Forms (CRFs). Informed consent
must be obtained and the participant must be registered
prior to the participant undergoing procedures that are
specific to the study and are beyond standard routine
care at the participating site.
In order to proceed to R1, participants must have
achieved at least SD (according to the IMWG criteria).
It is foreseen that not all participants will achieve a
minimum of SD. Hence, to enable the study to retain
enough power for the statistical analysis of the research
question associated with the second randomisation (R2),
we require a minimum of 284/406 participants to
proceed to R1. The anticipated dropout rate is based on
previous experience in the Myeloma X trial. Participants
who do not show at least SD will cease trial treatment
and will receive off-trial treatment at the discretion of
the treating clinician. The trial opened to recruitment in
March 2017 and is due to close to recruitment in Febru-
ary 2022 or when the planned sample sizes have been
reached, whichever is earlier.
Table 2 ACCoRd study first randomisation inclusion and
exclusion criteria
Inclusion criteria
1. Registered into the ACCoRd trial and received four to six cycles of
ITD re-induction chemotherapy according to the protocol
2. Responded [(s)CR, VGPR or MR] or have SD according to the IMWG
Uniform Response Criteria for Multiple Myeloma
3. Adequate stem cell mobilisation defined as ≥ 2 × 106 CD34+ cells/
kg or ≥ 2 × 108 peripheral blood mononuclear cells (PBMCs)/kg
available for transplantation (including cells stored from a previous
harvest)
•Inclusion criteria 5{4}a, 6{5} and 7{6} specified in Table 1 apply to R1
inclusion criteria and hence are not included in this table
7. Adequate pulmonary function within 14 days before registration:
(a) Adequate respiratory functional reserve (delineated by KCO/DLCO
(carbon monoxide diffusion in the lung) of ≥ 50%). No evidence of
a history of pulmonary disease. If a significant history, then a review
by a respiratory medicine physician is required.
8. Adequate cardiac function within 12 weeks before registration:
(a) Left ventricular ejection fraction (LVEF) ≥ 40%. Note: repeat
confirmation of cardiac function is needed if treatment is given
between this assessment and registration
Exclusion criteria
1. Received any therapy for their relapsed disease other than local
radiotherapy, therapeutic plasma exchange or Myeloma XII (ACCoRd)
ITD treatment, prior to first randomisation. (Radiotherapy sufficient to
alleviate or control pain of local invasion is permitted, but not within
14 days prior to randomisation. Participants who have received
hemi-body radiation since relapse will not be eligible.)
• Exclusion criteria 2{2}, 5{3} and 6{4} specified in Table 1 apply to R1
exclusion criteria and hence are not included in this table
5. Any contraindication to protocol treatment that would make the
participant ineligible
a5{4} notation is to be interpreted in the following way: Table 1 inclusion criteria
5 is equivalent to Table 2 inclusion criteria 4, etc.
Table 3 ACCoRd study second randomisation inclusion and
exclusion criteria
Inclusion criteria
1. Registered into the ACCoRd trial and received ASCT as per
randomised treatment allocation according to the protocol
• Inclusion criteria 2{2} (excluding SD response), 4{3}a, 5{4}, 6{5} and 8{7}
specified in Table 2 apply to R2 eligibility criteria and hence are not
included in this table
6. Adequate pulmonary function within 14 days before randomisation:
(a) No clinical evidence of deterioration in pulmonary function since
first randomisation. If there is evidence of clinical deterioration, then
adequate respiratory functional reserve (delineated by KCO/DLCO
(carbon monoxide diffusion in the lung) of ≥ 50%)
8. If female and of childbearing potential, must have a negative
pregnancy test within 14 days prior to randomisation, performed by a
healthcare professional in accordance with the Celgene Thalidomide
Pregnancy Prevention Programme
Exclusion criteria
1. Received any therapy for their relapsed disease other than local
radiotherapy, therapeutic plasma exchange or Myeloma XII (ACCoRd)
protocol treatment prior to second randomisation. (Radiotherapy
sufficient to alleviate or control pain of local invasion is permitted, but
not within 14 days prior to randomisation. Participants who have
received hemi-body radiation since relapse will not be eligible.)
• Exclusion criteria 2–5{2–5} specified in Table 2 apply to R2 eligibility
and hence are not included in this table
a4{3} notation is to be interpreted in the following way: Table 2 inclusion criteria
4 is equivalent to Table 3 inclusion criteria 3. In this case, the notation does not
transfer back to Table 1
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Registration and randomisation
Following confirmation of written informed consent and
eligibility, an authorised member of staff at the trial re-
search site will register participants immediately into the
study. Registration will be performed centrally using the
Leeds Clinical Trials Research Unit (CTRU) automated
24-h telephone and web registration and randomisation
system (Gen24). Following successful registration, partici-
pants will undergo four to six cycles of ITD re-induction
and will subsequently be assessed for response.
Following registration and re-induction therapy, an
authorised member of staff at the trial research site will ran-
domise participants into the study. Randomisation will be
performed centrally using the Gen24 system. At the first
randomisation (R1), following completion of ITD re-
induction chemotherapy, eligible participants (see Table 2
for details) will be randomised on a 1:1 basis to augmented
ASCT (ASCTAug) or conventional ASCT (ASCTCon).
A Gen24-generated minimisation program that incorpo-
rates a random element will be used to ensure treatment
groups are well balanced for specific participant characteris-
tics. For R1 these are: β2-microglobulin concentration at
first relapse (< 3.5, 3.5–< 5.5, ≥ 5.5 mg/L, unknown); length
of first remission or plateau (< 18 months, 18–24 months
or > 24 months); response to ITD re-induction therapy (<
VGPR or ≥VGPR); cytogenetic risk status at trial entry
(Standard Risk, High-Risk or Unknown), as defined by
Palumbo et al., in the presence of del(17p) and/or transloca-
tion t(4;14), and/or translocation t(14;16) [25] and mainten-
ance treatment received in first-line setting (Yes or No).
At approximately 100 days following completion of
trial ASCT and assessment for response, eligible partici-
pants (see Table 3 for details) will undergo the second
1:1 randomisation (R2) to receive consolidation and
maintenance or no further treatment.
A Gen24-generated minimisation program that incorpo-
rates a random element will be used to ensure treatment
groups are well balanced for the following participant
characteristics for R2: allocated ASCT (conventional or
augmented) and response to allocated ASCT (< VGPR or
≥VGPR).
Protecting against bias
The study is an open-label trial which will use an inde-
pendent randomisation service, and analyses will be
conducted on an intention-to-treat (ITT) basis. The trial
is administered by the Chief and Principal Investigators
and the CTRU in accordance with Good Clinical
Practice (GCP) guidelines. Response and relapse will be
assessed using the IMWG International Uniform
Response Criteria using blood and urine samples (and
bone marrow, where required), unless progression of
myeloma occurs as an isolated bone lesion, growth of a
plasmacytoma or an increase in plasma cells in the bone
marrow without a change in M-protein, where a tissue
histological examination will be performed.
External confirmation of disease progression and
response data will be performed on samples of blood
and urine at baseline, post re-induction treatment,
100 days post-transplant, post-consolidation (or 8
weeks post-R2 in the no further therapy arm) and at
disease progression at a central laboratory. Samples
will be forwarded by centres to relevant laboratories
for central analysis. All disease progression and re-
sponse data will be further confirmed by blinded clin-
ical review coordinated by the CTRU.
Pre-registration assessments
Assessments to be performed prior to participant regis-
tration to the ACCoRd study and starting treatment are
a physical examination (including systolic and diastolic
blood pressure, height, weight, BSA, vital signs, assess-
ment for peripheral neuropathy, for example, using the
Neurotoxicity Assessment Tool); ECOG PS and Revised
International Staging System (R-ISS) classification; med-
ical history (including details of concomitant disease and
medication, prior chemotherapy and ASCT and previous
trial participation); Haematopoietic Cell Transplantation
(HCT) Comorbidity Index score; FBC; serology of hepa-
titis B and C; urea and electrolytes, liver function tests,
albumin, lactate dehydrogenase, C-reactive protein, cal-
cium, creatinine and β2-microglobulin; estimated cre-
atinine clearance; paraprotein, serum free light chains,
serum total (class-specific) immunoglobulins and urinary
light chain detection (quantification where available);
bone marrow aspirate and trephine (if available) within 4
weeks prior to registration; a pregnancy test; cardiac
function (LVEF) within 12 weeks prior to registration;
pulmonary function (KCO/DLCO) and an axial skeletal
survey (performed as part of the restaging process in
accordance with IMWG recommendations and local
policy, and can be supplemented by computed tomog-
raphy (CT), magnetic resonance imaging (MRI) or other
investigation when appropriate in accordance with local
practice). Additionally, for the central investigation, a set
of compulsory samples must be provided to the appro-
priate lab, to include peripheral clotted blood (10 ml)
and random urine sample (10 ml); bone marrow aspirate
(2 ml) in ethylenediaminetetraacetic acid (EDTA) and
bone marrow trephine (where available) in formalin,
embedded in paraffin/wax block or on slides (See Fig. 2
for assessment schedule details).
For the purposes of optional translational research re-
quiring separate consent, the following samples should
be taken prior to the start of ITD, for patients who have
consented to the translational research investigations:
peripheral blood (20 ml) in EDTA; serum (10 ml) and
bone marrow aspirate (4–5 ml).
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Intervention
All participants will be registered at trial entry and will
receive re-induction therapy with four to six 28-day
cycles of ixazomib (4 mg/day on days 1, 8 and 15), thal-
idomide (100 mg/day on days 1–28) and dexamethasone
(40 mg/day on days 1, 8, 15 and 22) (ITD), in order to
reach maximum response. At the end of re-induction,
participants will be assessed for response and will be
asked to complete the pre-randomisation QoL question-
naires, unless participants have not consented or with-
drawn from the QoL study element of the trial.
Participants will then go on to peripheral blood stem cell
(PBSC) mobilisation and harvest, which may be omitted
if adequate PBSCs are available from previous mobilisa-
tion and harvest. Following this, participants who
achieve at least stable disease (SD) will be randomised
on a 1:1 basis to receive either conventional ASCT
(ASCTCon), using melphalan (200 mg/m
2/day on day
−1), or augmented ASCT (ASCTAug), using melphalan
with ixazomib (ixazomib 4 mg/day on days −4 and −1
and melphalan 100 mg/m2/day on days −3 and −2).
Participants will then be assessed for response 100 days
post-ASCT and asked to complete the QoL question-
naires. All participants achieving or maintaining MR or
better following trial ASCT will undergo R2 to consoli-
dation and maintenance or no further treatment. Partici-
pants randomised to R2 will receive consolidation with
two 28-day cycles of ITD (ixazomib (4 mg/day on days
1, 8 and 15), thalidomide (100 mg/day on days 1–28)
and dexamethasone (40 mg/day on days 1, 8, 15 and
22)) and maintenance with ixazomib (4 mg on days 1, 8,
and 15) given as a 28-day cycle until disease progression.
Participants will be asked to complete QoL question-
naires at 12 and 24 months post-R2 at their clinic visit,
unless participants have not consented or have
previously withdrawn from the QoL study (See Fig. 2 for
assessment schedule details).
Follow-up
All participants registered into the ACCoRd trial and re-
ceiving re-induction treatment will be followed up until
progression, death or withdrawal from trial. Participants
showing PD at the response assessment at the end of
ITD re-induction will be treated off trial with trial
follow-up concluded. Participants undergoing R1 and
showing SD or PD at 100 days post-ASCT will be
treated off trial and their disease progression and death
data collected. Participants undergoing R2 with a ran-
domisation to no further treatment will be followed up
for 8 weeks post-R2 and on a 3-monthly basis thereafter
until disease progression. Subsequently patients will be
followed up annually until death or end of study. All R2
participants will be followed up until progression, and
subsequently death on an annual basis.
Safety reporting
Adverse events (AEs) are any untoward medical occur-
rences in a participant or clinical trial subject who re-
ceives a medicinal product which do not necessarily
have a causal relationship with this treatment. AEs can
be defined as any unintentional, unfavourable clinical
signs or symptoms; any new illness or disease, or the de-
terioration of existing disease or illness; or any clinically
relevant deterioration in any laboratory assessments or
clinical tests. Due to the nature of myeloma and its
treatment, participants are likely to experience several
AEs throughout the course of the disease.
All AEs, both related and unrelated to myeloma treat-
ment, occurring from the first dose of ixazomib until 60
days after treatment will be reported and will be evalu-
ated in accordance with the National Cancer Institute
Common Terminology Criteria for Adverse Events
V4.03 (NCI-CTCAE).
Serious adverse events (SAEs) are defined as any unto-
ward medical occurrences or effects that result in death;
or are life threatening (at the time of the event); or re-
quire in-patient hospitalisation or prolongation of exist-
ing hospitalisation; or result in persistent or significant
disability or incapacity; or result in a congenital anomaly
or birth defect; or any other important medical event.
For all participants who undergo R2, SAEs should be re-
ported from the date of first dose of study drug until 60
days after the date of disease progression. For all partici-
pants who do not proceed to R2, SAEs should be re-
ported until 60 days after the last dose of study drug.
Serious adverse reactions (SARs) are to be reported from
registration throughout the trial.
SARs are events that are fatal or life-threatening; require
or prolong hospitalisation; are significantly or permanently
disabling or incapacitating; constitute a congenital anom-
aly or a birth defect; or jeopardise the participant and re-
quire medical or surgical intervention to prevent one of
the outcomes listed above. SARs are SAEs that are
deemed to be possibly related to any dose administered of
any trial treatment. Suspected unexpected serious adverse
reactions (SUSARs) are SARs which are not listed in the
reference safety information for that medicinal product.
SARs and SUSARs should be reported from the start of
treatment and for the duration of the trial. An independ-
ent Data Monitoring and Ethics Committee (DMEC) will
review the safety and ethics of the trial. The CTRU will
prepare detailed unblinded reports for the DMEC at ap-
proximately yearly intervals. Unblinded safety updates are
also prepared for review at 6-monthly intervals whilst par-
ticipants are receiving trial treatment.
Data collection
Data will be collected using paper CRFs and entered into
a validated trial database by the CTRU. A validation
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check program will be incorporated into the trial data-
base to verify the data, and discrepancy reports will be
generated for resolution by the investigator. Priority vali-
dations will be incorporated into the validation program
to ensure that any discrepancies related to participant
rights or safety are expedited to sites for resolution. Data
will be monitored for quality and completeness by the
CTRU. Missing data will be chased until received, and
confirmed as not available, or the trial is at analysis. The
CTRU/Sponsor will reserve the right to intermittently
conduct source data verification exercises on a sample of
participants, which will be carried out by staff from the
CTRU/Sponsor. Source data verification will involve dir-
ect access to participant notes at the participating
hospital sites and the central collection of copies of con-
sent forms and other relevant investigation reports. Data
will be held on a secure server at the University of Leeds
and paper CRFs stored in a locked unit, both of which
are accessible only to authorised trial staff.
Statistical methods and analysis
The CTRU statisticians will be responsible for the statis-
tical analysis, and a final statistical analysis plan will be
written before any analyses are undertaken.
All analyses will be conducted on the ITT population,
where participants will be included according to the
treatment to which they were randomised regardless of
eligibility, whether they prematurely discontinued treat-
ment or did not comply with the regimen. A per-
protocol (PP) analysis, where participants will be in-
cluded according to the treatment they received, will be
considered for the primary endpoints if there are a
considerable number of protocol violators. The safety
population will consist of all participants who receive at
least one dose of the relevant study treatment.
An overall two-sided 5% significance level will be used
for all efficacy endpoint comparisons. For the primary
endpoints, this will be adjusted to account for the formal
interim analyses. Interim statistical summaries will be
presented to the DMEC in strict confidence at approxi-
mately yearly intervals.
Safety analyses will summarise all SUSARs, SARs,
SAEs, AEs, ARs and treatment-related mortality rates as
well as laboratory changes. Safety data will be presented
by treatment group for the safety population in addition
to relationship to study treatment.
Formal interim analysis for lack of benefit (or harm in
the language of Freidlin and colleagues [26]) will be
undertaken when 25% of required participants have
completed response assessments at 100 days post-ASCT
after R1 (46 patients). If the lower 95% confidence
bound for the odds ratio comparing the ≥VGPR rate in
ASCTCon and ASCTAug is above 1 (where an odds ratio
above 1 means that the ASCTAug group is worse), then
treatment in this group may be halted. Formal interim
analyses for early efficacy will be undertaken when 50%
of required participants have completed response assess-
ments at 100 days post-ASCT (91 participants) after R1
and when 50% of required PFS events have been ob-
served (96 events) in follow-up after R2. These interim
analyses will be assessed against a pre-specified signifi-
cance level of 0.005 indicating possible overwhelming
evidence of early efficacy. All interim analysis will be ad-
visory with changes to the study at the discretion of study
oversight committees. If the interim analysis for R1 leads
to changes in the study protocol, study registration would
continue to answer the question posed at R2. This would
be achieved by extending the registration phase to include
the selected treatment option at R1 for all subsequently
treated patients before R2. No other formal analysis of the
study is planned before the participants have attained the
primary endpoints, i.e. all randomised participants have
had response evaluated 100 days post-R1 or all rando-
mised participants have been followed up for a minimum
of 2 years post-R2. The key secondary endpoint, OS, will
be evaluated after all continuing participants have been
followed up for a minimum of 4 years post-R2. Analysis of
other endpoints will be undertaken alongside these
analyses, as appropriate.
For R1, the number and proportion of participants in
each response category (sCR, CR, VGPR, etc.) will be
summarised by allocated treatment and exact 95% CIs
will be calculated. The difference in proportions for each
response category in ASCTCon and ASCTAug will be
presented with corresponding 95% CIs.
Allocated treatment groups will be compared with re-
spect to the proportion achieving remission (VGPR or CR)
using logistic regression to adjust for the minimisation fac-
tors. The need for PBSC re-mobilisation will be recorded
and adjusted for in these analyses, as appropriate. The sig-
nificance levels will be adjusted to account for the interim
analyses for early efficacy. The O’Brien and Fleming
α-spending function [27] will be used, suggesting α-levels
of 0.047 for the final analyses and 0.005 for the interim
analyses. Hence, there will be evidence to suggest superior-
ity of ASCTAug and ASCTCon if the p values for the initial
randomisation result odds ratios are ≤ 0.047. Parameter es-
timates, odds ratios and corresponding 95% CIs, degrees
of freedom, test statistics and p values will be presented
for each factor in the models. Residuals and predicted
values produced from the models will be examined to as-
sess the assumptions of the statistical models.
For R2, causes of progression in all participants will be
summarised, and the proportions of participants with
each underlying cause will be calculated. To compare
ITD consolidation and ixazomib maintenance with no
treatment, Cox regression analysis will be used to ana-
lyse PFS accounting for the minimisation factors. The
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significance levels will be adjusted to account for the
interim analyses for early efficacy. Participants who are
alive and not experiencing progression will be censored
at the last date known to be alive and progression-free.
Parameter estimates, HRs and corresponding 95% CIs,
degrees of freedom, test statistics and p values will be
presented for each variable in the model.
The proportional hazards assumptions will be assessed
by plotting the hazards over time for each treatment
arm and using appropriate statistical tests. If evidence is
found to support the violation of the proportional haz-
ards assumption, then alternative appropriate analysis
methods will be investigated.
Secondary endpoint analysis of OS and other time-to-
event endpoints will be analysed using similar methods
to those described for the PFS primary endpoint. MRD
negativity will be analysed using similar methods to
those described for the response primary endpoint. AEs
will be summarised using CTCAE categories. QoL will
be summarised using mean scores adjusted for baseline
and 95% CIs for each European Organisation for Re-
search and Treatment of Cancer (EORTC) QLQ-C30
and EORTC QLQ-MY20 module symptom, role and
functioning domain at each assessment time point. Simi-
lar summaries will be produced for quality-adjusted life
years (QALYs), as scored by the EQ-5D questionnaire.
A series of subgroup and exploratory analyses will be
undertaken. Cytogenetic subgroups will be analysed to
explore a number of specific hypotheses, including the
effect on PFS, OS, time to progression and response.
Some examples of what will be studied include chromo-
some 14 translocations and abnormalities of chromo-
somes 1p, 1q, 13q and 17p. In addition, other regions
considered to be of interest will be analysed according to
the statistical analysis plan. Other subgroup and explora-
tory analyses may also be performed and will be de-
scribed in the statistical analysis plan or separate
analyses plans related to translational work.
Protocol amendments
The trial opened to recruitment in March 2017 using
protocol version 3, dated 26 September 2016. An amend-
ment to protocol version 4 is anticipated to be approved
in March 2018, focusing on relaxing exclusion criteria 1 at
registration, which stated that if the participant received
dexamethasone (up to a maximum of 200 mg within 30
days prior to registration) he/she would not be eligible for
the trial. Protocol version 4 will remove the 30-day restric-
tion to allow more participants into the trial whilst main-
taining the maximum dose permitted.
Trial organisation and administration
The trial was developed by the ACCoRd Trial Manage-
ment Group (TMG), with the support of the UK
Myeloma Research Alliance (UK-MRA or NCRI
Myeloma Subgroup). The trial is sponsored by the
University of Leeds (Research & Innovation Centre/
Faculty of Medicine & Health, Leeds Teaching
Hospitals NHS Trust/University of Leeds, St James
University Hospital, Leeds, LS9 7TF and is registered
(ISRCTN10038996, EudraCT Number 2016-000905-
35). A core project team, a TMG, a Trial Steering
Committee (TSC) and a DMEC have been established.
The independent DMEC review the safety and ethics of
the trial alongside trial progress, and the overall direc-
tion is overseen by the TSC. Six-monthly interim safety
reports are presented to the DMEC with a full review
annually. The committee members will determine the
subsequent frequency of review. The DMEC, in light of
the interim data and of any advice or evidence they
wish to request, will advise the TSC if there are any
concerns or reasons why the trial should not continue.
The results of the study will be published in peer-
reviewed journals and will be presented at relevant na-
tional and international conferences. The CTRU will
control the final trial dataset, and any requests for ac-
cess will be reviewed by the TMG and TSC, subject to
existing contractual arrangements with the funders. To
maintain the scientific integrity of the trial, data will
not be released prior to the end of the trial, either for
trial publication or oral presentation purposes, without
the permission of the TSC or the Chief Investigator.
Discussion
The study has had an encouraging start to recruitment.
The trial has been able to open centres to recruitment at
a rapid pace, with 22 centres open to recruitment in the
first week and 65 centres open to recruitment within 4
months. The pace of recruitment is likely due to a num-
ber of factors.
Patient attitudes towards ASCT may have changed
[28], given the results of NCRI Myeloma X. Participants
no longer have the option of not receiving ASCT on
study. In addition, NICE guidance recommends second
ASCT to eligible patients who have completed re-
induction without PD and have a response duration of
between 12 and 24 months after their first ASCT [7].
These factors could contribute to participants and their
treating physicians being more likely to agree to partici-
pate in ACCoRd, as the control arm is the basis of
national standard-of-care second-line treatment for this
patient group. In addition, participants are gaining ac-
cess to treatment with ixazomib, currently not available
outside of clinical studies.
A wider contributing factor is potentially the success-
ful recruitment nationally to investigator-initiated trials
led by the NCRI, which have provided practice-changing
results. Some of the success in recruitment could be
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explained by considering the excellent rate of recruit-
ment to MRC Myeloma IX (1970 participants) and
NCRI Myeloma XI (4420 participants), which have a
high overlap of centres with ACCoRd. This benefits
from the well-developed relationship with the coordinat-
ing CTRU that has evolved over more than 20 years.
Trial status
The ACCoRd trial opened to recruitment in March 2017.
At the time of submission, the trial had recruited 140 par-
ticipants, thus surpassing predicted recruitment for Febru-
ary 2019, 31 participants have gone through R1 and 4
participants have gone through R2.
Additional file
Additional file 1: The ACCoRd Trial SPIRIT checklist. (DOCX 52 kb)
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